… with sorafenib were 86 days in the sorafenib/erlotinib arm and 123 days in the sorafenib/…
erlotinib for patients in the sorafenib/erlotinib group were 86 and 157 days, respectively. …

… These trials of sorafenib plus gefitinib and erlotinib plus bevacizumab seem to echo our
findings in their nonoverlapping toxicity profiles, suggesting that simultaneous inhibition of the …

… sorafenib/erlotinib versus 1.77 months for placebo/erlotinib (… for sorafenib/erlotinib versus
4.5 months for placebo/erlotinib … for sorafenib/erlotinib was suggested among 43 patients with …

… sorafenib in the sorafenib plus erlotinib and sorafenib plus placebo arms were 768 and 773
mg, respectively, while the median daily doses of erlotinib … in the sorafenib plus erlotinib arm, …

… ) in the sorafenib plus erlotinib group compared with sorafenib plus placebo, … sorafenib
plus erlotinib group (13). Despite this trial not demonstrating a benefit for the addition of erlotinib …

… with sorafenib in the treatment of patients with advanced pancreatic … cancer patients treated
with erlotinib, was performed. Patients received sorafenib 400 mg daily along with erlotinib …

… This study identified the MTD and DLTs for sorafenib and erlotinib … —sorafenib and erlotinib—of
this trial and discuss the sequential accrual design in detail. Sorafenib and erlotinib were …

… phase II study, we compared treatment with single agent sorafenib to the combination of
sorafenib/erlotinib, in patients who relapsed after benefitting from single agent erlotinib. …

… designed a clinical trial of combining erlotinib and sorafenib in advanced NSCLC patients. In
… combination of sorafenib and erlotinib in previously treated patients with advanced NSCLC. …

… of sorafenib monotherapy in NSCLC (6–8). In addition, a phase I study established the safety
and tolerability of combining sorafenib and erlotinib … of sorafenib combined with erlotinib in …